TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent before initiation of any study-specific activities/procedures~* Subject has completed FOURIER (Study 20110118) while still receiving assigned investigational product.~Exclusion Criteria:~* Investigational product was permanently discontinued during FOURIER for any reason, including an adverse event or serious adverse event~* Subject is currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(ies) within less than 4 weeks. Other investigational procedures while participating in this study are excluded~* Subject is not likely to be available to complete protocol-required study visits or procedures and/or to comply with required study procedures to the best of the subject's and investigator's knowledge~* Subject has a history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion~* Subject has a known sensitivity to any of the active substances or excipients (eg, sodium acetate) to be administered during dosing~* Female subject is pregnant or breastfeeding or is planning to become pregnant or planning to breastfeed during treatment with evolocumab and within 15 weeks after the end of treatment with evolocumab~* Female subjects of childbearing potential who are not willing to use an acceptable method(s) of effective birth control during treatment with evolocumab and for an additional 15 weeks after the end of treatment with evolocumab are excluded

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- evolocumab (AMG 145) (Type: EXPERIMENTAL): All subjects are randomized to a single arm and will receive evolocumab 140mg every two weeks (Q2W) or 420mg monthly (QM) according to subject's preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SR-BI and Antiviral Treatment Response in HCV

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Naive to IFN treatment and other experimental antiviral or immunosuppressive therapy before enrollment.~2. Serum alanine aminotransferase levels, at least, twice the upper limit of normal on two occasions within the previous 6 months.~Exclusion Criteria:~1. Positive for hepatitis B surface antigen~2. Positive for human immunodeficiency virus antibody~3. Had a known history or evidence of autoimmune liver disease, inheritable disorders, renal insufficiency, malignancy~4. Had a history of daily alcohol consumption greater than 20 gram or active drug abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HCV group (Peginterferon alfa-2a) (Type: None): A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
- Control Group (Type: None): There were 153 healthy controls negative for anti-HCV enrolled simultaneously from the database of Health Management Center.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human-centered Design and Communities of Practice to Improve Delivery of Home-based Tuberculosis Contact Investigation in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Health centre inclusion criteria:~1. Reporting ≥12 index TB cases per month to the national TB program,~2. Located outside the borders of but ≤180 km from Kampala District~Health centre exclusion criteria:~1) Administrators of the health centre do not agree to participate in the study~Individual inclusion criteria for index persons with TB (also known as index TB patients or TB cases):~1. Being an adult or child recorded as a new TB case in the on-site National TB and Leprosy Programme TB treatment register, and~2. Residing ≤40 km from the enrolling health centre,~Individual exclusion criteria for index persons with TB :~1. Lacking the capacity to consent to contact investigation,~2. Lacking close contacts,~3. Having possible or confirmed drug-resistant TB,~4. Previously received TB contact investigation within the last 2 months, and~5. Not agreeing to refer close contacts for contact investigation.~Inclusion criteria for close contacts:~1) Being an adult or child reporting ≥12 cumulative hours with the TB patient inside an enclosed space within the previous 3 months,~Exclusion criteria for close contacts:~1. Lacking the capacity to consent to contact investigation,~2. Currently taking treatment for active TB, and~3. Not agreeing to participate in contact investigation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard Implementation Strategy Period (Type: ACTIVE_COMPARATOR): During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
- Enhanced Contact Investigation Intervention Period (Type: EXPERIMENTAL): The enhanced contact investigation strategy includes 4 implementation facilitation tools and 3 continuous quality improvement techniques and will be delivered as a branded package named for an inspirational Luganda phrase that is translated as We are together with you. Implementation facilitation tools include 1) a TB education pamphlet, 2) a contact identification algorithm, 3) an instructional video on sputum collection, and 4) community health riders who transport clients, community health workers, and sputum samples by motorcycle. The continuous quality improvement techniques delivered as the community of practice package include 1) community of practice meetings, 2) audit and feedback reports and 3) a group chat application.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy~Exclusion Criteria:~* poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of meibomian gland dysfunction and dry eye~* At least 18 years of age~* Willing to comply with randomization, attend all study visits and follow patient instructions~* Habitual soft contact lens wearer 2 to 18 hours/day and 4 to 7 days/week~* No change in contact lens type or dimensions for the past 3 months~* Clinician assessment of acceptable contact lens fit and disinfecting solution~* Tear film interferometry of 100 units or less~Exclusion Criteria:~* Systemic disease conditions that cause dry eye~* Use of systemic medications known to cause dryness~* History of any of the following ocular conditions in the past 3 months: surgery, trauma, Herpes infection, recurrent inflammation, punctal plug insertion or punctal occlusion~* Presence of any of the following active conditions: ocular infection, ocular inflammation, moderate to severe allergic conjunctivitis, severe eyelid inflammation, eyelid abnormality that affects lid function, or ocular surface abnormality that compromises corneal integrity~* Use of other treatments for meibomian gland dysfunction or dry eye except over the counter lubricants or dietary supplements~* Participation in another ophthalmic drug or device trial in the past month~* Employee, relative of employee or associate of the clinical site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LipiFlow (Type: EXPERIMENTAL): Single 12-minute LipiFlow treatment
- Untreated Control (Type: NO_INTERVENTION): Untreated Control (No Intervention)
- Crossover LipiFlow Treatment (Type: EXPERIMENTAL): Crossover LipiFlow treatment of the untreated control group after 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes mellitus (T2DM) and have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months prior to screening visit.~* Have HbA1c between ≥7.0% and ≤10.5%.~* Have a stable weight (± 5%) for at least 3 months before screening.~* Have a body mass index (BMI) ≥23 kilograms per meter squared (kg/m²) at screening.~Exclusion Criteria:~* Have type 1 diabetes mellitus.~* Have had chronic or acute pancreatitis any time prior to study entry.~* Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment.~* Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss.~* Have an estimated glomerular filtration rate \<30 mL/minute/1.73 m² \[for participants on metformin, estimated glomerular filtration rate \<45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)\]~* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months.~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2.~* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once a week.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age \>18 \< 75 years~* Histologically/cytologically confirmed locally advanced, unresectable pancreatic cancer~* At least one lesion measurable with CT or MRI scan~* Performance Status (ECOG) 0-1 at study entry~* Life expectancy of at least 3 months~* Adequate marrow, liver and renal function~* Effective contraception if the risk of conception exists (in the Informed Consent for the patients the descriptions of possible contraceptives is reported)~Exclusion Criteria:~* Previous chemotherapy or radiotherapy for pancreatic cancer~* Severe cardiovascular disease~* Thrombotic or embolic events~* Acute or subacute intestinal occlusion or history of inflammatory bowel disease~* Known hypersensitivity to study drug~* Known drugs or alcohol abuse~* Pregnant or breastfeeding women~* Previous or concurrent malignancy; except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and with evidence of no recurrence for at least 5 years prior to randomization~* Unable to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- nab-paclitaxel and gemcitabine (Type: EXPERIMENTAL): ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
- Gemcitabine (Type: ACTIVE_COMPARATOR): ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female (at least 1 year post-menarche) children and adolescents (aged 10 -17 years) with heterozygous familial hypercholesterolemia (HeFH)~Exclusion Criteria:~* Certain medical conditions and lab test results~* History of a reaction to rosuvastatin or other statin drugs~* Use of specified disallowed medications

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- rosuva 5 (Type: ACTIVE_COMPARATOR): rosuvastatin 5 mg
- rosuva 10 (Type: ACTIVE_COMPARATOR): rosuvastatin 10 mg
- rosuva 20 (Type: ACTIVE_COMPARATOR): rosuvastatin 20 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- rosuva ol (Type: OTHER): rosuvastatin open label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 12- to 15-month-old males and females with no active liver disease~* A negative history of hepatitis A, measles, mumps, rubella, chickenpox, and/or zoster~Exclusion Criteria:~* Males and females previously vaccinated with hepatitis A, measles, mumps, rubella, and/or chickenpox vaccine~* Any immune deficiency~* History of allergy to any of the vaccine components~* History of any seizure disorder

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: ProQuad™ 0.5 mL injection (2 doses \~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® Treatment in Pediatric Lower Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum weight of 10 kg/22 lb~* Cerebral palsy with dynamic muscle contracture /spasticity of the ankle~Exclusion Criteria:~* Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease~* Uncontrolled epilepsy~* Botulinum Toxin therapy of any serotype for any condition within the last 6 months~* History of surgical intervention of the lower study leg or planned surgery of any limb during the study~* Previous casting of the study limb for spasticity within 6 months or with a dynamic splint within 3 months, or planned casting or dynamic splinting for spasticity of the study limb or affected upper limb during the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX® 4 U/kg (Type: EXPERIMENTAL): Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
- BOTOX® 8 U/kg (Type: EXPERIMENTAL): Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
- Normal Saline (Placebo) (Type: PLACEBO_COMPARATOR): Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to (\>=) 18 years~* Histologically confirmed predominantly non-squamous NSCLC that is unresectably advanced, metastatic or recurrent (with or without adenocarcinoma)~* No contraindications to Avastin® according to the current Summary of Product Characteristics (SmPC) for Avastin®~* Therapeutic decision for Avastin® as first line treatment in combination with platinum-based chemotherapy was taken individually and independent of the non-interventional trial.~Exclusion Criteria:~N/A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: None): Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus requiring treatment with at least 1500 mg but not greater than 2550 mg of a maximum tolerated dose of Metformin therapy for at least 8 weeks prior to screening.~* HbA1c \>= 7.0% and \<= 10.0 %~* Body mass index \<= 40 kg/m2~* Fasting C-peptide \>= 1 ng/dL~Exclusion Criteria:~* Symptomatic poorly controlled diabetes~* Recent cardiac or cerebrovascular event~* Serum creatinine \>= 1.5 mg/dL for males and \>= 1.4 mg/dL for females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin + Metformin (A) (Type: EXPERIMENTAL): Pioglitazone 15-45 mg (as needed for rescue)
- Saxagliptin + Metformin (B) (Type: EXPERIMENTAL): Pioglitazone 15-45 mg (as needed for rescue)
- Saxagliptin + Metformin (C) (Type: EXPERIMENTAL): Pioglitazone 15-45 mg (as needed for rescue)
- Placebo+ Metformin (D) (Type: PLACEBO_COMPARATOR): Pioglitazone 15-45 mg (as needed for rescue)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete